Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia

Experimental Oncology

Volumn 30, Issue 2, 2008, Pages 157-159

  Horacek, J M ^a,c   Tichy, M ^a,c   Jebavy, L ^a,c   Pudil, R ^b   Ulrychova, M ^a   Maly, J ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acute myeloid leukemia; Anthracyclines; Cardiac biomarkers; Cardiotoxicity; Chemotherapy; Glycogen phosphorylase BB

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CREATINE KINASE MB; CYTARABINE; DAUNORUBICIN; FATTY ACID BINDING PROTEIN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE BB; IDARUBICIN; MITOXANTRONE; MYOGLOBIN; TROPONIN I; TROPONIN T;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; EVALUATION; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; TREATMENT OUTCOME;

AGED; ANTHRACYCLINES; BIOLOGICAL MARKERS; FEMALE; GLYCOGEN PHOSPHORYLASE; HEART; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 46749128979     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
2. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25: 237-47.
3. Ganz WI, Sridhar KS, Ganz SS, et al. Review oftests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-70.
4. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf 2002; 25: 301-11.
5. Fink FM, Genser N, Fink C, et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995; 25: 185-9.
6. Clark SJ, Pippon M, Hemsworth S, et al. Cardiac troponin T following anthracycline chemotherapy in children and adolescents. J Chemother 2007; 19: 332-4.
7. Horacek JM, Pudil R, Jebavy LS, et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 2007; 29: 309-13.
8. Apple FS, Wu AH, Mair J, et al. Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810-24.
9. Azzazy HM, Pelsers MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem 2006; 52: 19-29.
10. Peetz D, Post F, Schinzel H, et al. Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 2005; 43: 1351-8.